Retrospective, subset analyses of tumor tissue samples from small clinical trials have demonstrated that tumor KRAS gene mutations are associated with lack of response to both of the EGFR-targeted monoclonal antibodies approved for use in colorectal cancer, cetuximab and panitumumab. The gene discussed is KRAS; the disease is neoplasm.